L. Zhang

2.3k total citations · 1 hit paper
29 papers, 1.1k citations indexed

About

L. Zhang is a scholar working on Oncology, Organic Chemistry and Surgery. According to data from OpenAlex, L. Zhang has authored 29 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Organic Chemistry and 5 papers in Surgery. Recurrent topics in L. Zhang's work include Lung Cancer Treatments and Mutations (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Nausea and vomiting management (3 papers). L. Zhang is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Nausea and vomiting management (3 papers). L. Zhang collaborates with scholars based in China, United States and United Kingdom. L. Zhang's co-authors include Dissaya Pornpattananangkul, C.‐M. Hu, Ching-Wen Huang, Jian R. Lu, Thomas Andrew Waigh, Mingrui Liao, Haoning Gong, Xuzhi Hu, Henry Cox and Pier Luigi Zinzani and has published in prestigious journals such as Journal of Clinical Oncology, Nano Letters and Langmuir.

In The Last Decade

L. Zhang

26 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of Nanoparticles for Antimicrobial Drug Delivery

2010 626 citations L. Zhang, Dissaya Pornpattananangkul et al. Current Medicinal Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Zhang China	9	302	259	183	169	163	29	1.1k
Ching-Wen Huang Taiwan	6	200 0.7×	147 0.6×	122 0.7×	141 0.8×	141 0.9×	8	745
Songling Han China	20	476 1.6×	413 1.6×	88 0.5×	337 2.0×	497 3.0×	46	1.5k
Mohsen Chiani Iran	21	349 1.2×	360 1.4×	60 0.3×	195 1.2×	277 1.7×	66	1.2k
Rossella Farra Italy	25	721 2.4×	398 1.5×	149 0.8×	154 0.9×	239 1.5×	62	1.6k
Katharina Richter Australia	20	381 1.3×	71 0.3×	140 0.8×	134 0.8×	149 0.9×	58	1.2k
Clara I. Colino Spain	14	341 1.1×	159 0.6×	78 0.4×	185 1.1×	212 1.3×	20	945
Seyed Ebrahim Alavi Iran	26	460 1.5×	692 2.7×	95 0.5×	170 1.0×	540 3.3×	76	1.7k
Hasan Ebrahimi Shahmabadi Iran	24	312 1.0×	539 2.1×	82 0.4×	164 1.0×	412 2.5×	63	1.3k
Zhanyi Sun China	21	886 2.9×	258 1.0×	334 1.8×	66 0.4×	235 1.4×	41	1.6k
Beata Kolesińska Poland	21	642 2.1×	262 1.0×	508 2.8×	143 0.8×	256 1.6×	111	1.5k

Countries citing papers authored by L. Zhang

Since Specialization

Citations

This map shows the geographic impact of L. Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Zhang more than expected).

Fields of papers citing papers by L. Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Zhang. The network helps show where L. Zhang may publish in the future.

Co-authorship network of co-authors of L. Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of L. Zhang. A scholar is included among the top collaborators of L. Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Zhang. L. Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Wang, Fangfang Xiang, L. Zhang, et al.. (2024). Associations between inflammatory markers and carotid plaques in CKD: mediating effects of eGFR–a cross-sectional study. BMC Nephrology. 25(1). 374–374. 1 indexed citations

Zhang, L., et al.. (2024). Electrical Impedance Spectroscopy with Bacterial Biofilms: Neuronal-like Behavior. Nano Letters. 24(7). 2234–2241. 7 indexed citations

Fang, Wenfeng, Yuanyuan Zhao, Yan Huang, et al.. (2023). 1504TiP HARMONi: Randomized, double-blind, multi-center, phase III clinical study of ivonescimab or placebo combined with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have progression following EGFR-TKI treatment. Annals of Oncology. 34. S847–S847.

Qu, Nan, Mingqing Liao, Yuan Cheng, et al.. (2023). Accelerating Density Functional Calculation of Adatom Adsorption on Graphene via Machine Learning. Materials. 16(7). 2633–2633. 5 indexed citations

Fan, Peili, et al.. (2022). 69O First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive oesophageal squamous cell carcinoma (ASTRUM-007): A randomised, double-blind, multicentre phase III study. Annals of Oncology. 33. S1457–S1458. 2 indexed citations

Zhao, Hongyun, Shun Zheng, Yi Ma, et al.. (2021). 43P Assessment of biomarker kinetics for ADG106 (anti-CD137 agonist) as monotherapy or combined with toripalimab. Annals of Oncology. 32. S1389–S1390. 1 indexed citations

Yang, Yunpeng, Hao Wang, Shenhong Qu, et al.. (2021). 121O RATIONALE 309: A randomized, global, double-blind, phase III trial of tislelizumab (TIS) vs placebo, plus gemcitabine + cisplatin (GP), as first-line treatment for recurrent/metastatic nasopharyngeal cancer (RM-NPC). Annals of Oncology. 32. S1430–S1430. 8 indexed citations

Liu, Huayang, Ke Fa, Xuzhi Hu, et al.. (2021). How do chain lengths of acyl-l-carnitines affect their surface adsorption and solution aggregation?. Journal of Colloid and Interface Science. 609. 491–502. 4 indexed citations

Fang, Jian, Yuanyuan Zhao, Baohui Han, et al.. (2021). 94P Patient-reported outcomes (PROs) following sintilimab (sint) plus pemetrexed (pem) and platinum (plt) based chemotherapy as first-line therapy for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase III study (Orient-11). Annals of Oncology. 32. S1415–S1415. 1 indexed citations

10.

Zhang, L., Yunpeng Yang, Zhaoguang Wang, et al.. (2020). ID:1329 ORIENT-11: Sintilimab + Pemetrexed + Platinum as First-Line Therapy for Locally Advanced or Metastatic Non-Squamous NSCLC. Journal of Thoracic Oncology. 15(10). e41–e41. 4 indexed citations

11.

Yang, Yunpeng, Zhaoguang Wang, Jian Fang, et al.. (2020). LBA57 MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC). Annals of Oncology. 31. S1186–S1186. 1 indexed citations

12.

Zhang, L., Jian R. Lu, & Thomas Andrew Waigh. (2020). Electronics of peptide- and protein-based biomaterials. Advances in Colloid and Interface Science. 287. 102319–102319. 28 indexed citations

13.

Dechaphunkul, Arunee, et al.. (2018). Efficacy of single dose NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of nausea in patients receiving high dose cisplatin. Annals of Oncology. 29. ix131–ix131. 1 indexed citations

14.

Zhang, L., Shun Lü, J. Feng, et al.. (2017). A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC). Annals of Oncology. 29(2). 452–458. 66 indexed citations

15.

Rotolo, Federico, Jean‐Pierre Pignon, Sophie Marguet, et al.. (2016). Surrogate endpoints for overall survival in loco-regionally advanced nasopharyngeal carcinoma: Results from the individual patient data meta-analysis MAC-NPC2. Annals of Oncology. 27. vi328–vi328. 1 indexed citations

16.

Zinzani, Pier Luigi, Julie M. Vose, M. S. Czuczman, et al.. (2013). Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study. Annals of Oncology. 24(11). 2892–2897. 90 indexed citations

17.

Zhang, L., Dissaya Pornpattananangkul, C.‐M. Hu, & Ching-Wen Huang. (2010). Development of Nanoparticles for Antimicrobial Drug Delivery. Current Medicinal Chemistry. 17(6). 585–594. 626 indexed citations breakdown →

18.

Akilesh, Shreeram, et al.. (2008). Acute renal allograft thrombosis in 'seronegative' antiphospholipid syndrome. Clinical Kidney Journal. 2(2). 181–182. 4 indexed citations

19.

Gao, Fei, Quanyu Wang, X. Wang, et al.. (2007). Agonistic Anti‐4‐1BB Antibody Promotes the Expansion of Natural Regulatory T Cells While Maintaining Foxp3 Expression. Scandinavian Journal of Immunology. 66(4). 435–440. 58 indexed citations

20.

Zhao, Chong, et al.. (2002). [Correlation between the kinetics of plasma EBV DNA levels and clinical response during treatment in patients with nasopharyngeal carcinoma].. PubMed. 21(8). 817–22. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact